Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
The Lancet. Oncology|October 17, 2021
Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysisJennifer J Gao, Joyce Cheng, Tatiana M Prowell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2023
US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast CancerPreeti Narayan, Asma Dilawari, Christy Osgood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2022
FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast CancerMelanie Royce, Christy Osgood, Flora Mulkey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2025
US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast CancerSuparna Wedam, Preeti Narayan, Haley Gittleman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2024
US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer With <i>PIK3CA</i>/<i>AKT1</i>/<i>PTEN</i> AlterationsAsma Dilawari, James Buturla, Christy Osgood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2025
US Food and Drug Administration Approval Summary: Ribociclib With an Aromatase Inhibitor in the Adjuvant Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Stage II and III High-Risk Early Breast Cancer Treatment SettingJennifer J Gao, Tatiana M Prowell, Haley Gittleman, et al.
Pageof 1